The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Stock picking tips

Fri, 06th Mar 2020 15:39

* Bourses fall in virus worries
* Europe's bank at lowest since 2009

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Thyagaraju Adinarayan
(thyagaraju.adinarayan@tr.com), Joice Alves (joice.alves@tr.com), Julien Ponthus
(julien.ponthus@tr.com) in London.

STOCK PICKING TIPS (1540 GMT)
Here are some stock picking tip from BNP Paribas' Edmund Shing.
"You will find that stocks that are sensitive to bonds, relatively speaking are caught up
better than the market overall. Now the stocks that tend to be more bond sensitive are
defensive, and tend to be located in sectors like healthcare and utilities for instance," he
told us in an interview.
"That is often because they have lots of debt," he adds.
Shing also gives hints on how to pick the best stocks in the coronavirus era, beyond the big
utilities names.
"It's very difficult: One strategy you can employ is looking for companies that are falling
off," he says, if you don't find an explanation - like a profit warning or something
fundamentally wrong - this company may be your pick.
Smaller companies often suffer when there is a big sell-off, because in panic selling
investors rush to take some profits off the table, but "in fact the companies that suffer the
sharpest fall sometimes can be those which have very strong fundamentals, which explain why they
had such good performance before the crisis".
"When fundamentals and valuations are diverging, there is a chance that at some point the
price will shoot up, and prices at some point rejoins fundamentals".
(Joice Alves)
*****


WHAT A RIDE FOR UTILITIES! (1411 GMT)
The sector is losing some ground today, although it's still outperforming the others in the
daily coronavirus sell-off we've been seeing of late in Europe. Year-to-date it has been
a darling among investors surviving the meltdown in markets.


European utilities have delivered a double-digit return so far this year and there is more
to that than the bond yield, DB's James Brand writes. Here is his guess why:
- The turn in earnings cycle and return to growth
- Enthusiasm for ESG
- The coronavirus driven rotation into defensives
"Interestingly our correlation analysis suggests that this could be justified just by the
drop in bond yields. However, our view is that robust medium-term earnings growth and long-term
investment opportunities related to ESG may be better reasons to remain bullish," Brand adds.

(Joice Alves)
*****


CARNAGE! (1323 GMT)
Are markets losing it? Bear market territory is not too far away for many bourses. The
pan-European STOXX 600 index has now fallen close to 16% from record highs. Wall Street
meanwhile is getting ready for a 3.2% drop.
"We think that equities will need more visibility if they are to manage to build a viable
bottom or to be able to tap into the power afforded by a reasonable sense of relief – for
example, as a result of easing in the momentum of new coronavirus cases also outside China,"
Christian Stocker at UniCredit says.




(Thyagaraju Adinarayan)
*****

EUROPE'S BANKS AT LOWEST SINCE 2009 (1110 GMT)
European banks are down close to 4% and have now hit their lowest since 2009 as the
coronavirus scare cuts deeper into global markets.
We're past bear territory with a fall of about 25% since February.
Seems there's a combination of straight recession fears (with all that means in terms of
toxic NPLs quickly building up) and expectations of another ECB cut which would bite hard into
margins again.
Germany's 10-y govt bond yield fell to -0.740%, which is very, very close to its record low
of -0.743 of September 2019.
"The situation of the European banking sector is completely different from what it was in
2009", Jerome Legras, head of research at Axiom Alternative Investments just told us.
"There’s the psychological aspect of hitting the same level but I’m not more worried about
their solvency than I was three weeks ago", he added.
"Profitability is a different story though..."

Take a look:


(Joice Alves and Julien Ponthus)
*****



OPENING SNAPSHOT: NOT THE TIME FOR TRAVEL & LEISURE (0823 GMT)
European bourses open in negative territory as coronavirus fears continue to drag down the
stock market.
The pan European index is on track for its third straight day of declines and
needless to say the travel and leisure space is lagging behind all the other sectors,
down more than 3%.
In terms of single stocks, Italy's Prysmian started the day among the top movers,
down almost 10%, after it warned that core profit will not grow this year, blaming trade
tensions, higher tariffs and the coronavirus outbreak.
Capita's capitulation continues as brokers cut price targets after the company's
update yesterday sent shares down 40%.

(Joice Alves)
*****


STOCKS TO WATCH: INFINEON, AIRBUS, ESSILORLUXOTTICA (0745 GMT)
Futures point to another blow for European bourses with 2% plus declines across the board as
coronavirus anxiety continues to grip investors.
In the corporate world, Infineon in focus after a Bloomberg reported that
Washington recommended Trump to block the German chipmaker's proposed $10 billion deal to buy
Cypress Semiconductor as it poses a security risk.
Airbus shares could take a hit as it got zero orders for February due to
coronavirus, but worth remembering that the recent sell-off has likely priced-in most of the bad
news.
EssilorLuxottica is the other name to watch out for after the company said it
expects is first-half revenues to be slower (I'd let you guess the why here).
Non-virus news: British pharma AstraZeneca seen down 2% after its combination
treatment for a form of bladder cancer failed to meet the main goal.

(Thyagaraju Adinarayan)
*****


ANOTHER DAY, ANOTHER SELL-OFF (0637 GMT)
Stocks are seen opening sharply lower again today on top of yesterday's ugly sell-off that
took bank stocks into bear market territory along with autos, travel & leisure and oil & gas.
The number of global coronavirus cases is fast approaching the 100k mark with fears of a
massive economic damage sending shivers down investors' spine.
Financial spreadbetters IG expect London's FTSE to open 114 points lower at 6,592,
Frankfurt's DAX to open 255 points lower at 11,690 and Paris' CAC to open 116 points lower at
5,246.
"Markets have shifted from pricing temporary China weakness to a more protracted global
event, which will see a good chunk of global GDP go up in smoke," said Stephen Innes, chief
market strategist at AxiCorp.

(Thyagaraju Adinarayan)
*****





(Reporting by Joice Alves, Julien Ponthus and Thyagaraju Adinarayan)

More News
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.